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A B S T R A C T
Purpose: To evaluate the effect of diurnal variability on cortical excitability using single pulse
transcranial magnetic stimulation (TMS), in drug naive patients with juvenile myoclonic epilepsy (JME)
and to look for any differences in cortical excitability between males and females.
Methods: Thirty drug-naive patients with JME and 10 healthy controls were studied. Resting motor
threshold (RMT), motor evoked potential (MEP), the duration of central motor conduction time (CMCT)
and cortical silent period (CSP) were measured, twice, ﬁrst early in the morning and again in the
afternoon of the same day.
Results: Diurnal variation with higher evening values of CMCT and CSP were observed in the control
group. In the study group, diurnal variation in RMT, CMCT and CSP was found with higher values in the
morning than in control group. However, only the raised values of CSP [mean, 110.7 ms, morning and
96.44 ms, evening] were of statistical signiﬁcance [p = 0.005, morning and 0.039, evening] as compared
to controls. In the study group, males had higher values of RMT, CMCT and CSP than in females. However,
the CMCT in males was lower in the evening study than in females. Further, RMT and morning CMCT was
lower in females than in controls. In females, the morning CSP [mean, 100.91 ms, morning versus
87.86 ms, evening] was signiﬁcantly prolonged [p = 0.017, morning versus 0.221, evening] as compared
to controls.
Conclusion: The study is suggestive of the existence of impaired supraspinal/intracortical inhibitory
circuits which may account for the hyperexcitability of the motor system being prominent in the
morning among drug naı¨ve patients with JME. In this study, increased activity of cortical inhibitory
networks, as evidenced by prolonged cortical silent period existed among drug naı¨ve JME patients, but
was found to be signiﬁcant only in female patients. This may explain the increased seizure susceptibility
in this cohort, at this time of the day and an increased manifestation of JME in females.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Juvenile myoclonic epilepsy (JME) represents 5–11% of all
epilepsy cases.1 Its incidence has been estimated at approximately
1 per 100,000 population, while its prevalence varies from 10 to 20
per 100,000.2 It affects both male and female patients equally,3
although a female predominance has been described.4–6
JME is characterized by arrhythmic, brief myoclonic seizures
and generalized tonic clonic seizures which occur mostly withinAbbreviations: JME, juvenile myoclonic epilepsy; RMT, resting motor threshold;
MEP, motor evoked potential; CMCT, central motor conduction time; CSP, cortical
silent period; TMS, transcranial magnetic stimulation; MEP, motor evoked
potential; APB, abductor pollicis brevis.
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http://dx.doi.org/10.1016/j.seizure.2013.05.001the ﬁrst few hours of awakening in the morning. It may also be
associated with absence seizures. The clinico-electrical manifesta-
tions of JME bear a close relationship to the sleep–wake cycle,
especially during the transitional phase from sleep to wakeful-
ness.3 This relationship is perhaps due to the ﬂuctuations in the
cortical excitability with the circadian rhythm.7
Transcranial magnetic stimulation (TMS), ﬁrst introduced by
Barker in 1985, is used for studying various disorders including
epilepsy, especially to understand the excitability of the motor
cortex.8–17 The two studies, available in the literature, to assess the
diurnal changes in the cortical excitability show conﬂicting results.
One of these studies was conducted on patients on long term anti-
epileptic drugs, found no effect.17 The second study, on ten drug
naive patients, reported an increase in cortical excitability in the
morning.7 Further there is no documented study on the difference
in cortical excitability between both sexes, in drug naive patients,
with JME.
Central motor conduction time (CMCT) is an estimation of the
conduction time in central motor pathways from motor cortex tovier Ltd. All rights reserved.
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have reported conﬂicting results.18,19
The aim of our study was to determine whether there was any
diurnal variation in cortical excitability in drug naive patients with
JME and whether the cortical excitability differed between males
and females.
2. Materials and methods
All patients with JME attending the Neurology OPD (January
2010–May 2011) were evaluated for their clinical proﬁle, EEG and
CT/MRI. Thirty drug naive JME patients, with onset of seizures
mostly between 12 and 18 years (range 7–24 years) and clinical
history of myoclonic and generalized tonic clonic seizures,
predominantly within the ﬁrst 2 h after awakening in the morning,
with normal neurological examination, EEG showing generalized
spike-wave/polyspike-wave complexes with frequencies of 4–6 Hz
with normal background activity and no abnormality on cranial CT/
MRI were included in the study. Ten, age and sex matched, controls
were also studied. Patients with cardiac pacemaker, vagal nerve
stimulator or intracranial metallic implants, previous neurosurgical
intervention or fracture of the skull, any psychiatric illness,
pregnancy, taking anti-epileptic drugs, sedative hypnotic drugs,
beta blockers or any other drug abuse were excluded from the study.
The clinical details of the patients meeting our inclusion criteria
were recorded, especially any co-morbid condition and its drug
therapy. EEG and CT/MRI study were done on all patients. The
patients were grouped according to age [11–15 years, 16–20 years,
21–25 years, and 26–30 years] and seizure frequency. If a patient
had no seizure in a month or so but subsequently experienced one
or more seizures in a week, he/she was assigned the appropriate
group of seizure occurrence in a week.
A written and informed consent was obtained from all the
patients enrolled for this study. The study had its approval from the
Institutional Ethics Committee.
2.1. Transcranial magnetic stimulation
The subjects were made to sit comfortably in an armchair. Hand
dominancy was conﬁrmed by Edinburgh Handedness Test. Motor
evoked potential (MEP) responses were recorded using surface
electrodes from the abductor pollicis brevis (APB) muscle of
dominant hand. The active electrode was placed on the muscle
belly and the reference electrode over the ﬁrst metacarpo
phalangeal joint. Single-pulse transcranial magnetic stimulation
was performed using a butterﬂy coil over the vertex, connected to
Magstim Rapid Stimulator. MEP responses were recorded by
Medelec Synergy device.
The motor threshold was determined when the subject was in a
resting position. Resting motor threshold (RMT) was deﬁned as the
stimulus intensity at which a peak-to-peak MEP amplitude of
50 mV was obtained in at least 5 out of 10 consecutive trials, i.e.,
the intensity required to get a 50 mV MEP appearing with 50%
probability. During active muscle contraction, the patient held
approximately 30% of the maximal voluntary contraction, and the
shortest onset latency and the highest amplitude of 5 consecutive
MEPs were obtained and latencies were measured (active motor
threshold or cortical latency).
Cervical roots were stimulated over the spinous process of
the 7th cervical vertebra, at maximal stimulator output, with the
subject in a sitting position with a slight degree of neck ﬂexion.
Central motor conduction time (CMCT) was calculated by
subtracting the latency of cervical response from the latency of
cortical MEP response.
During cortical silent period (CSP) measurement, i.e., the period
of suppression of the voluntary EMG activity following MEP whilesubjects held maximal contraction of the APB muscle, stimulus
intensity was adjusted to the maximal output of the magnetic
stimulator. Five consecutive stimuli were delivered. The duration
of CSP was measured from the end of MEP until the resumption of
EMG activity and the shortest CSP value was selected for
evaluation.
All the parameters were assessed in the morning, within 2 h of
awakening from sleep [7.00–9.30 AM according to each individu-
al’s sleep–wake cycle] and in the evening [4.00–6.00 PM] of the
same day. The patients were instructed not to have dinner on the
eve prior to the test and to avoid the afternoon nap on the day of
the study. All women of child bearing age had their TMS study
performed during the same phase of menstrual cycle. None of the
patients or controls had sleep deprivation prior to the study.
2.2. Statistical analysis
The data obtained from patients as well as controls was
compared using the Mann–Whitney test. The differences between
the morning and evening variables were evaluated with Wilcoxon
Signed Ranks test. Kruskal–Wallis test with post hoc correction
was used to ﬁnd out any signiﬁcant differences in various TMS
parameters in accordance with the demographic and other
variables. The analysis was performed on windows SPSS 16.0
software.
3. Results
30 patients [11 males; 19 females (63%)] constituted the study
group. The mean age of the patients was 18.77  3.27 years
[ranging between 14 and 24 years]. While the control group, had 10
patients [4 males; 6 females (60%)] with mean age 20.7  2.63 years
[ranging between 16 and 24 years], the mean age, at onset of seizures,
was 15.8  4.23 years [ranging between 7 and 23 years] while the age,
at onset of habitual seizures, was 16.17  3.9 years [ranging between
7 and 23 years]. The mean duration of seizures was 3.23  3.11 years
[ranging between 1 and 16 years].
Myoclonic jerks were seen in all the 30 patients (100%);
generalized tonic clonic seizures, in 25 patients (83%), and absence
seizures, in 2 patients (7%). The proﬁle of seizures, as recorded, is in
Table 1. The parents of one patient had a consanguineous marriage.
Birth and developmental history were normal in all the patients.
None of the patients or the controls had experienced febrile
seizures. Six patients (20%), in the study group, had a family history
of epilepsy. Two patients had pulmonary tuberculosis, in the past,
while another patient had a history of tubercular cervical
lymphadenitis. All three patients had already received appropriate
and adequate anti-tubercular treatment. Another patient had
haemophilia.
3.1. EEG abnormalities
All 30 patients had paroxysmal generalized spike and wave or
polyspike and wave activity. Bifrontal onset preceding generalized
discharges was seen in 1 patient (3.3%), focal slow waves in 2
patients (6.6%) and independent frontal spikes or sharp waves
were observed in 4 patients (13.3%).
3.2. TMS parameters
Diurnal variation was observed in RMT, CMCT and CSP in the
study group but, only in CMCT and CSP, in controls. Higher mean
values were noted in morning than in evening, in the study group.
On the contrary, mean values of CMCT and CSP were higher in the
evening than in morning, in controls. Though the study group
recorded higher values of RMT, CMCT and CSP than in controls,
Table 1
Proﬁle of seizures.
Group with seizures Females Males Total %
Occurrence n % n %
Myoclonic seizures
1 per day in one week 10 52.6 3 27.27 13 43.33
More than 1 per day in one week 7 36.8 5 45.45 12 40
1 in a month and or 1 in 6 months 2 10.52 2 18.18 04 13.33
1 in more than 6 months to 1 year 0 0 0 0 0 0
1 in more than 1 year 0 0 1 9.09 1 3.33
Total 19 100 11 100 30 100
GTCS
1 per day in one week 0 0 0 0 0 0
More than 1 per day in one week 4 22.22 2 2.04 6 24
1 in a month and or 1 in 6 months 5 27.77 2 2.04 7 28
1 in more than 6 months to 1 year 2 11.11 1 14.28 3 12
1 in more than 1 year 7 38.38 2 28.57 9 36
Total 18 100 7 100 25 100
Last seizures occurrence before study
Within 2 days 5 26.31 4 36.36 9 30
More than 2 days to 1 week 2 10.52 4 36.36 6 20
More than 1 week to 1 month 6 31.57 2 18.18 8 26.66
More than 1 month to 1 year 5 26.31 1 9.09 6 20
More than 1 year 1 5.26 0 0 1 3.33
Total 19 100 11 100 30 100
Table 2
TMS parameters in patients and controls.
Parameter Morning Evening
Study group (n = 30) Control group (n = 10) Study group (n = 30) Control group (n = 10)
Mean with SD Range Mean with SD Range p Mean with SD Range Mean with SD Range p
Resting motor threshold
(stimulus intensity %)
53.07  10.95 38–80 50.8  5.2 45–60 0.801 52.93  10.75 40–80 50.8  5.2 45–60 0.765
Central motor conduction
time (ms)
7.78  2.04 3–11.6 7.17  1.51 4.5–9.3 0.365 7.3  1.69 4.1–10.6 7.44  1.23 5.7–9.9 0.778
Cortical silent period (ms) 110.7  38.4 42–176.1 73.67  26.1 51.3–119 0.005 96.44  29.86 34.4–151.2 75.18  26.7 38.4–125.7 0.039
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morning, versus 0.039, evening] as compared to controls (Table 2).
In the study group, males had higher values of RMT, CMCT and CSP
than in females. However, CMCT in the evening study was lower in
males than in females. Resting motor threshold values were lower
in females and higher in males, in both morning and evening, in
the study group than in controls. The cortical silent period, in the
morning study, was signiﬁcantly prolonged [p = 0.017, morning,
versus 0.221, evening] in females patients, compared to controls
(Table 3). On comparing the recorded TMS parameters between the
two sexes, statistical signiﬁcance was found in evening recorded
CSP, in the study group compared to controls. The comparativeTable 3
Diurnal TMS parameters in males and females in study group and controls.


















7.30  2.18 7.85  1.17 0.598 8.60  1.49 6.15  1.50 
Cortical silent
period (ms)
100.91  34.59 68.78  25.03 0.017 127.57  40.35 81.00  29.52 values in morning, in study group and controls were: RMT, p = 0.17
versus 0.45; CMCT, p = 0.09 versus 0.06; CSP, p = 0.08 versus 0.75,
respectively and in evening study, the corresponding values were:
RMT, p = 0.16 versus 0.45; CMCT, p = 0.73 versus 1.00; CSP, p = 0.03
versus 1.00, respectively.
3.3. TMS variables in relation to seizures (Tables 4–6)
No signiﬁcant difference was observed between the various
parameters of TMS and the frequency of seizures; myoclonus,












0.286 51.11  10.92 51.33  6.15 0.606 56.64  11.55 50.00  4.08 0.256
0.026 7.51  1.49 7.25  0.92 0.975 6.93  2.00 7.72  1.72 0.489
0.104 87.86  30.56 71.75  21.94 0.221 111.25  22.89 80.32  35.75 0.078
Table 4
TMS parameters in relation to frequency of myoclonus.
Frequency of myoclonus Study group
Morning Evening
Females Males Females Males
n Mean with SD p n Mean with SD p n Mean with SD p n Mean with SD p
Resting motor threshold (stimulus
intensity %)
0.35 0.93 0.30 0.89
1 per day in one week 10 47.50  8.99 3 56.67  5.77 10 47.60  9.35 3 58.33  7.63
More than 1 per day in one week 7 52.86  11.12 5 56.00  14.74 7 53.57  13.13 5 54.60  16.30
1 in a month and or 1 in 6 months 2 60.00  0.00 2 55.50  13.45 2 60.00  0.00 2 57.50  10.60
1 in more than 6 months to 1 year 0 – 0 – 0 – 0
1 in more than 1 year 0 – 1 60.00  0.00 0 – 1 60.00  0.00
Total 19 50.79  9.94 11 56.45  10.64 19 51.11  10.92 11 56.64  11.55
Central motor conduction
time (ms)
0.48 0.79 0.57 0.34
1 per day in one week 10 7.39  2.41 3 8.93  2.34 10 7.45  1.26 3 6.43  2.02
More than 1 per day in one week 7 6.82  2.09 5 8.68  1.50 7 7.50  1.94 5 7.38  2.06
1 in a month and or 1 in 6 months 2 8.55  1.48 2 8.65  0.70 2 7.80  1.69 2 5.40  1.69
1 in more than 6 months to 1 year 0 – 0 – 0 – 0 –
1 in more than 1 year 0 – 1 7.20  0.00 0 – 1 9.30  0.00
Total 19 7.30  2.18 11 8.60  1.49 19 7.51  1.49 11 6.93  2.00
Cortical silent period (ms) 0.37 0.20 0.81 0.079
1 per day in one week 10 90.44  33.30 3 158.13  21.78 10 80.35  33.32 3 124.41  24.98
More than 1 per day in one week 7 110.95  35.81 5 100.38  37.95 7 92.08  25.41 5 96.96  21.07
1 in a month and or 1 in 6 months 2 118.20  38.18 2 141.35  49.14 2 110.70  34.78 2 125.70  15.69
1 in more than 6 months to 1 year 0 – 0 – 0 – 0 –
1 in more than 1 year 0 – 1 144.30  0.00 0 – 1 114.30  0.00
Total 19 100.91  34.59 11 127.57  40.35 19 87.86  30.56 11 111.25  22.89
Table 5
TMS parameters in relation to frequency of GTCS.
Frequency of GTCS Study group
Morning Evening
Females Males Females Males
n Mean with SD p n Mean with SD p n Mean with SD p n Mean with SD p
Resting motor threshold (stimulus
intensity %)
0.71 0.66 0.67 0.58
1 per day in one week 0 – 0 – 0 0
More than 1 per day in one week 4 44.75  7.08 2 55.00  7.07 4 44.75  7.08 2 55.00  7.07
1 in a month and or 1 in 6 months 5 53.00  12.04 2 52.50  10.60 5 54.00  14.74 2 49.00  15.55
1 in more than 6 months to 1 year 2 50.00  7.07 1 65  0.00 2 51.50  9.192 1 65.00  0.00
1 in more than 1 year 7 53.43  11.28 2 62.50  24.74 7 53.43  11.28 2 62.50  24.74
Total 18 51.00  10.18 7 57.86  12.53 18 51.44  11.37 7 56.86  13.93
Central motor conduction time (ms) 0.53 0.61 1.00 0.27
1 per day in one week 0 – 0 – 0 – 0 –
More than 1 per day in one week 4 6.10  2.10 2 9.30  3.25 4 6.85  0.44 2 6.00  2.26
1 in a month and or 1 in 6 months 5 6.56  2.20 2 7.90  0.14 5 7.54  2.06 2 7.25  0.49
1 in more than 6 months to 1 year 2 7.95  1.48 1 8.70  0.00 2 7.85  1.20 1 4.20  0.00
1 in more than 1 year 7 8.35  2.37 2 9.80  1.69 7 7.88  1.70 2 7.90  1.27
Total 18 7.31  2.24 7 8.95  1.70 18 7.55  1.52 7 6.64  1.71
Cortical silent period (ms) 0.93 0.23 0.56 0.22
1 per day in one week 0 – 0 0 0
More than 1 per day in one week 4 100.43  40.55 2 120.35  66.96 4 77.7  33.59 2 91.47  14.53
1 in a month and or 1 in 6 months 5 95.70  39.78 2 170.30  4.52 5 75.52  3.86 2 142.50  12.30
1 in more than 6 months to 1 year 2 107.90  44.26 1 176.10  0.00 2 94.35  51.97 1 136.80  0.00
1 in more than 1 year 7 103.94  36.43 2 85.20  4.52 7 97.11  36.95 2 91.70  1.83
Total 18 101.31  35.54 7 132.54  48.39 18 86.49  30.83 7 112.59  27.40
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No signiﬁcant difference was found between the various
parameters of TMS and the age of the patient, duration of the
illness, age at seizure onset, or presence or absence of generalized
tonic clinic seizures.4. Discussion
The present study demonstrated diurnal variation in patients
of JME with higher morning values for RMT in males and lower
in females and prolonged CSP. However, only cortical silent
period values [mean, 110.7 ms, morning and 96.44 ms, evening]
Table 6
TMS parameters in relation to occurrence of last seizure.
Last seizure within Study group
Morning Evening
Females Males Females Males
n Mean with SD p n Mean with SD p n Mean with SD p n Mean with SD p
Resting motor threshold (stimulus
intensity %)
0.41 0.94 0.21 0.80
Within 2 days 5 50.40  9.78 4 56.25  7.50 5 50.60  10.45 4 57.50  8.66
More than 2 days to 1 week 2 42.00  2.82 4 57.75  16.33 2 42.00  2.82 4 58.75  15.47
More than 1 week to 1 month 6 47.50  8.80 2 52.50  10.607 6 48.33  9.30 2 49.00  15.56
More than 1 month to 1 year 5 56.00  10.84 1 60.00  0.00 5 56.00  13.87 1 60.00  0.00
More than 1 year 1 64.00  0.00 0 – 1 64.00  0.00 0 –
Total 19 50.79  9.94 11 56.45  10.64 19 51.11  10.92 11 56.64  11.55
Central motor conduction time (ms) 0.60 0.84 0.80 0.17
Within 2 days 5 7.38  2.38 4 9.12  1.85 5 7.97  2.01 4 6.42  2.77
More than 2 days to 1 week 2 7.50  0.14 4 8.80  1.64 2 7.60  0.28 4 6.70  1.80
More than 1 week to 1 month 6 6.78  2.27 2 7.90  0.14 6 7.66  1.74 2 7.25  0.49
More than 1 month to 1 year 5 7.04  2.32 1 7.20  0.00 5 6.86  1.14 1 9.30  0.00
More than 1 year 1 11.00  0.00 0 – 1 7.40  0.00 0 –
Total 19 7.30  2.18 11 8.60  1.49 19 7.51  1.49 11 6.93  2.00
Cortical silent period (ms) 0.96 0.13 0.34 0.17
Within 2 days 5 112.36  37.97 4 142.10  38.56 5 105.66  37.33 4 111.31  21.92
More than 2 days to 1 week 2 103.40  14.42 4 87.50  14.21 2 78.40  31.11 4 94.80  14.13
More than 1 week to 1 month 6 99.72  38.44 2 170.30  4.52 6 74.05  24.09 2 142.50  12.30
More than 1 month to 1 year 5 96.26  39.94 1 144  0.00 5 84.54  29.70 1 114.30  0.00
More than 1 year 1 69.20  0.00 0 – 1 117.40  0.00 0 –
Total 19 100.91  34.59 11 127.57  40.35 19 87.86  30.56 11 111.25  22.89
Table 7
TMS parameters in relation to age of patients.
Age in years Study group
Morning Evening
Females Males Females Males
n Mean with SD p n Mean with SD p n Mean with SD p n Mean with SD p
Resting motor threshold
(stimulus intensity %)
0.12 0.20 0.08 0.48
11–15 years 3 47.67  7.63 4 57.50  16.58 3 46.67  9.29 4 55.75  18.59
16–20 years 10 51.50  10.89 4 51.50  5.97 10 51.30  12.48 4 53.75  7.50
21–25 years 6 51.67  10.32 3 61.67  2.88 6 52.50  10.36 3 61.67  2.88
26–30 years 0 – 0 – 0 – 0 –
Total 19 50.79  9.94 11 56.45  10.64 19 51.11  10.92 11 56.64  11.55
Central motor conduction
time (ms)
0.33 0.65 0.18 0.73
11–15 years 3 7.23  0.85 4 8.85  1.47 3 8.16  1.01 4 7.57  0.87
16–20 years 10 6.79  2.29 4 9.10  1.83 10 7.10  1.06 4 7.02  2.36
21–25 years 6 8.20  2.43 3 7.63  0.92 6 7.86  2.20 3 5.96  2.88
26–30 years 0 – 0 – 0 – 0 –
Total 19 7.30  2.18 11 8.60  1.49 19 7.51  1.49 11 6.93  2.00
Cortical silent period (ms) 0.48 1.00 0.63 0.97
11–15 years 3 146.25  15.29 4 127.75  49.27 3 112.43  38.46 4 117.10  30.19
16–20 years 10 88.99  32.90 4 124.72  33.45 10 81.47  24.85 4 105.76  15.06
21–25 years 6 98.13  27.15 3 131.13  52.79 6 86.25  34.80 3 110.76  27.96
26–30 years 0 – 0 – 0 – 0 –
Total 19 100.91  34.59 11 127.57  40.35 19 87.86  30.56 11 111.25  22.89
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evening].
Various studies on TMS, in epileptic patients, have reported
variable and conﬂicting results ranging from normal motor
threshold15,20,21 and cortical silent period duration15 to higher19
or lower22 motor thresholds and longer19–21 or shorter cortical
silent period duration.23 These differences have been attributed to
the type of epilepsy, antiepileptic drug intake and the methodology
used for evaluation like type of coil and stimulus intensity. Shorter
CMCT has been observed in patients with JME.19 Longer corticalsilent period has also been reported even in asymptomatic siblings
of JME.
Resting motor threshold mainly reﬂects neuronal membrane
excitability8,9,11,24 which largely depends on ion channel
conductivity25 and is believed to be sensitive to the effect of
most of the currently used AEDs.19,24 While the cortical silent
period reﬂects the activity of intracortical inhibitory interneur-
ons in primary motor cortex, leading to a failure of corticospinal
drive,8,9,11,26,27 GABAB-ergic intracortical circuits contribute to
the generation of transcranially evoked silent period with single
Table 8
TMS parameters in relation to the age at seizure onset.
Parameter Study group
Morning Evening
Females Males Females Males
n Mean with SD p n Mean with SD p n Mean with SD p n Mean with SD p
Resting motor threshold
(stimulus intensity %)
0.47 0.25 0.48 0.45
5–10 years 1 40.00  0.00 1 65.00  0.00 1 40.00  0.00 1 65.00  00
11–15 years 8 53.62  10.46 6 56.67  13.29 8 54.00  10.56 6 56.33  15.18
16–20 years 6 48.50  10.78 2 48.00  2.82 6 48.17  13.34 2 50.00  0.00
21–25 years 4 51.25  8.53 2 60.00  0.00 4 52.50  8.66 2 60.00  0.00
Total 19 50.79  9.94 11 56.45  10.64 19 51.11  10.92 11 56.64  11.55
Central motor conduction
time (ms)
0.77 0.60 0.12 0.35
5–10 years 1 7.60  0.00 1 8.70  0.00 1 7.80  0.00 1 4.20  0.00
11–15 years 8 6.92  2.11 6 9.03  1.82 8 7.36  1.37 6 7.00  1.57
16–20 years 6 6.36  2.21 2 8.80  0.28 6 6.97  1.04 2 8.20  2.26
21–25 years 4 9.40  1.39 2 7.10  0.14 4 8.55  2.25 2 6.85  3.46
Total 19 7.30  2.18 11 8.60  1.49 19 7.51  1.49 11 6.93  2.00
Cortical silent period (ms) 0.64 0.43 0.77 0.84
5–10 years 1 93.20  0.00 1 176.10  0.00 1 56.40  0.00 1 136.80  0.00
11–15 years 8 112.41  37.96 6 135.31  41.38 8 99.17  27.21 6 115.07  24.31
16–20 years 6 87.25  33.40 2 99.00  10.74 6 76.90  28.39 2 100.50  19.94
21–25 years 4 100.35  34.77 2 108.65  50.41 4 89.57  40.20 2 97.75  23.40
Total 19 100.91  34.59 11 127.57  40.35 19 87.86  30.56 11 111.25  22.89
Table 9
TMS parameters in relation to duration of illness.
Duration of illness (years) Study group
Morning Evening
Females Males Females Males
n Mean with SD p n Mean with SD p n Mean with SD p n Mean with SD p
Resting motor threshold
(stimulus intensity %)
0.47 0.17 0.48 0.25
1–5 years 15 49.07  9.09 10 55.60  10.81 15 49.47  10.58 10 55.80  11.82
6–10 years 2 62.00  2.82 0 – 2 62.00  2.82 0 –.
11–15 years 2 65.00  0.00 0 – 2 65.00  0.00 0 –
16–20 years 1 40.00  0.00 1 65.00  0.00 1 40.00  0.00 1 65.00  0.00
Total 19 50.79  9.94 11 56.45  10.64 19 51.11  10.92 11 56.64  11.55
Central motor conduction
time (ms)
0.007 0.63 0.12 0.16
1–5 years 15 7.24  2.09 10 8.60  1.57 15 7.55  1.52 10 7.21  1.88
6–10 years 2 9.25  2.47 0 – 2 8.20  1.13 0 –
11–15 years 2 4.00  0.00 0 – 2 5.20  0.00 0 –
16–20 years 1 7.60  0.00 1 8.70  0.00 1 7.80  0.00 1 4.20  0.00
Total 19 7.30  2.18 11 8.60  1.49 19 7.51  1.49 11 6.93  2.00
Cortical silent period (ms) 0.64 0.24 0.77 0.59
1–5 years 15 104.64  37.91 10 122.72  39.00 15 87.12  32.42 10 108.69  0.00
6–10 years 2 80.20  15.55 0 – 2 101.75  22.13 0 –
11–15 years 2 94.20  0.00 0 – 2 102.80  0.00 0 –
16–20 years 1 93.20  0.00 1 176.10  0.00 1 56.40  0.00 1 136.80  0.00
Total 19 100.91  34.59 11 127.57  40.35 19 87.86  30.56 11 111.25  22.89
V. Puri et al. / Seizure 22 (2013) 662–669 667pulse stimulation TMS. However, using paired stimuli one can
study the early part of silent period which is mediated by
GABAA-ergic circuits. These ﬁndings have been corroborated
with experimental studies.28–30
The intracortical facilitation reﬂecting activation of glutami-
nergic circuits can also be studied with paired stimulation.8
In epilepsy, the balance between cortical excitatory and
inhibitory activities tilts in favour of excitatory activity. There
are many types of seizures and different patterns of excitatory and
inhibitory neuronal events in epilepsy. Some animal models
suggest that the cortical hyperexcitability is the main processresponsible for idiopathic generalized epilepsy.31 Anticonvulsants
can depress the excitability of the motor cortex and motor
pathways in these epileptic patients.32
The physiological state of drowsiness has also been reported to
effect cortical excitability with an increase in mean motor
threshold and a decrease33 or increase34 in short intra cortical
inhibition in healthy individuals. Early morning myoclonic jerks,
the characteristic feature of JME35 as well as a common expression
of generalized epileptiform discharges in the mornings36 have
been attributed to a possible circadian dysrhythmia.7,37 The effect
of drowsiness and sleep stages on cortical excitability, in patients
Table 10
TMS parameters in relation to presence or absence of GTCS.
GTCS occurrence Study group
Morning Evening
Females Males Females Males
n Mean with SD p n Mean with SD p n Mean with SD p n Mean with SD p
Resting motor threshold
(stimulus intensity %)
0.27 0.54 0.68 0.92
Yes 17 51.35  10.38 7 57.86  12.53 17 52.12  11.09 7 56.86  13.93
No 2 46.00  1.41 4 54.00  7.11 2 42.50  3.53 4 56.25  7.50
Total 19 50.79  9.94 11 56.45  10.64 19 51.11  10.92 11 56.64  11.55
Central motor conduction
time (ms)
0.26 0.26 0.11 0.25
Yes 17 7.48  2.19 7 8.95  1.70 17 7.67  1.48 7 6.64  1.71
No 2 5.80  1.97 4 8.00  0.93 2 6.17  0.81 4 7.45  2.63
Total 19 7.30  2.18 11 8.60  1.49 19 7.51  1.49 11 6.93  2.00
Cortical silent period (ms) 0.30 0.48 0.71 0.83
Yes 17 103.50  35.36 7 132.54  48.39 17 87.18  31.64 7 112.59  27.40
No 2 78.90  21.07 4 118.87  24.20 2 93.70  26.72 4 108.90  15.21
Total 19 100.91  34.59 11 127.57  40.35 19 87.86  30.56 11 111.25  22.89
V. Puri et al. / Seizure 22 (2013) 662–669668with JME, may also contribute to seizures and epileptiform
discharges.33,34
Female sex hormones affect neuronal excitability in the
brain.38–40 Data from animal experiments have shown that
progesterone metabolites enhance the action of gamma-amino-
butyric acid41 while estradiol has excitatory effects, possibly acting
through the glutamate system.42 These effects are difﬁcult to
detect in women using single pulse trans-magnetic stimulation
techniques. However, paired transcranial magnetic stimulation
has shown changes in the excitability of cortical networks with
intra cortical inhibition [GABAA-ergic circuits]
43 as well as
facilitation44 during the various phases of menstrual cycle. JME
is a complex genetically determined disorder in which 15
chromosome loci, 3 Mendelian genes (a1-subunit of the GABAA
receptor [GABAA1], chloride channel 2 gene [CLCN2], as well as non
ion channel Myoclonin1/EFHC1) and 2 SNP susceptibility genes
have been identiﬁed to date.45
As our patients were drug naive, increased or lower motor
threshold or prolonged cortical silent period in the patients, an
indicator of cortical inhibitory networks, cannot be attributed only
to anticonvulsants. Therefore, there may be some endogenous
mechanism due to neural networking, operating in JME patients. In
a meta-analysis study of 40 patients with JME, signiﬁcantly lower
resting motor threshold were reported as compared to controls.46
However, contrary to the present study, statistically signiﬁcant
heterogeneity was also found among the ﬁve studies, which were
included in this meta-analysis.
Although cortical silent period was prolonged in all the JME
patients, as compared to the controls, yet it was statistically
signiﬁcant only in females. This cannot be attributed entirely to
the ﬂuctuations in female sex hormones during menstrual period,
as the TMS study was performed during the same part of
menstrual cycle, in all the female JME patients and controls. The
values recorded were higher among patients as compared to
the controls. Of course, our study was done with single pulse
stimulation and changes have been observed on paired stimula-
tion studies [GABAA-ergic circuits involvement] and not on single
pulse stimulation [GABAB-ergic circuits]. The signiﬁcant pro-
longed cortical silent period in females, reﬂecting impairment of
supraspinal and/or intracortical inhibitory mechanisms, may be
attributed to genetic factors with greater expression amongst
females. Most of the studies with JME, available in the literature,
are in patients on treatment with anti-epileptic drugs. The various
reported studies on drug naive patients have a smaller samplesize. As a result, the comparison between male and female data
could not be made.
In our study, morning central motor conduction time was lower
in females and increased in males with JME, than in controls. CMCT
changes in epileptic patients have been reported in two studies.
Hufnagel et al., observed that CMCT was signiﬁcantly lower in
patients with high frequency of seizures and after reduction of
anti-epileptic drugs.18 Akgun et al., did not observe any difference
in CMCT in JME patients as compared to controls, but found lower
CMCT as compared to asymptomatic siblings.19 The proposed
mechanism is perhaps endogenous facilitation of central motor
pathways by epileptiform activity.18
The diurnal effect we observed in patients with JME implies that
there exists a circadian variability in GABA-ergic mediated
inhibition leading to increased cortical excitability in the early
morning as compared to the afternoon in patients with JME. This
was even more signiﬁcant amongst females which could probably
be due to complex interaction between the dominant circadian
pacemaker [suprachiasmatic nuclei] in the brain through postsyn-
aptic GABA-ergic mediated pathways47,48 with hyper excitable
thalamo cortical networks, in patients with JME.7
Some authors did report precipitation of seizures following TMS,
in epileptic patients.49,50 On the contrary, various other studies did
not observe any seizure induced by single pulse or paired TMS in
epileptic patients.19,21,24 Schrader et al., observed that medically
intractable patients and low anti-epileptic drug serum level increase
the probability of inducing a seizure after TMS.51
We used single pulse stimulation and did not ﬁnd precipitation
of seizures in any of our drug naive patients.
Thus, the study concludes that a diurnal variability in cortical
excitability exists among drug naive JME patients. Further,
prolonged cortical excitability, an indicator of cortical inhibitory
networks, is statistically signiﬁcant amongst females with JME as
compared to controls.
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